Ozempic is a lower dose of semaglutide for type-2 diabetes only. The higher maintenance dose (2.4 mg) marketed as Wegovy is for weight loss.

A weight loss oral medication will be available within a year or so, and it will dramatically reduce manufacturing costs. (The autoinjectors are very well designed and nearly painless, but they're very expensive and the whole thing is disposable.) It will still probably require a cold chain. Rybelsus is already available for diabetes but it isn't approved for weight loss in 3 7, and 14 mg doses. Novo Nordisk will likely issue an 50 mg per day for maintenance dose.

IANAD: If one can, they should first try to limit portion size because the risk of thyroid cancers with long-term semaglutide use is unknown and nonzero. There's a real possibility of another Vioxx/Fen-Phen moment.